Martek downgraded to sell by Merrill

Martek Biosciences Corp. was downgraded to sell by Merrill Lynch analyst David Munno. While Roche selected Martek to produce a component of Tamiflu, Merrill does not expect the deal to provide meaningful value to Martek, possibly adding earnings per share of only $0.01-0.03. The stock is now above the top end of the analyst's fair value range of $16 to $35. Shares of the Columbia, Md., pharmaceutical company were down 62 cents, or 1.82%, at $33.36 on volume of 4,728,909 shares versus the three-month running average of 1,010,000 shares. (Nasdaq: MATK)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.